Skip to main content
Clinical Trials/NCT05052203
NCT05052203
Enrolling By Invitation
Not Applicable

Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis (REQOVERY)

Hjalmar Bouma1 site in 1 country120 target enrollmentSeptember 28, 2021
ConditionsSepsisInfection

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Sepsis
Sponsor
Hjalmar Bouma
Enrollment
120
Locations
1
Primary Endpoint
DNA methylation (epigenetics) using the Illumina MethylationEPIC kit. Changes in DNA methylation at gene promoter/enhancer sites will be correlated through the NetworkAnalyst platform.
Status
Enrolling By Invitation
Last Updated
2 years ago

Overview

Brief Summary

Sepsis is a life-threatening dysregulated immune response to infection associated with multi-organ failure and a high mortality rate.While researchers have focused mainly on acute sepsis, post-sepsis care of survivors has long been neglected despite the observation that many sepsis survivors suffer from debilitating post-sepsis syndrome. This syndrome is characterized by frequent hospital readmissions and increased mortality due to persistent immune dysfunction, cardiovascular disease, and cognitive impairment, causing poor quality of life and a substantial burden on the healthcare system. Disconcertingly, the number of sepsis survivors at risk for hospital readmission continues to rise.7 Of the post-sepsis symptoms, post-sepsis immunosuppression is perhaps the most clinically important. While sepsis presents as an initial phase of hyperinflammation (a "cytokine storm"), it is followed by an immunosuppressive phase that is now understood to last weeks to months and predisposes survivors to lethal secondary infections and sepsis recurrence. A third of deaths eight years post-sepsis are caused by recurrent sepsis.We hypothesize that changes in the transcriptome and DNA methylome in immune cells of survivors might be the underlying driver for prolonged immunosuppression, and may also be correlated with long-term morbidity and mortality post-sepsis, as well as other symptoms of post-sepsis syndrome including PTSD and cardiovascular disease.

Registry
clinicaltrials.gov
Start Date
September 28, 2021
End Date
December 2023
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Hjalmar Bouma
Responsible Party
Sponsor Investigator
Principal Investigator

Hjalmar Bouma

Internist and Research Fellow

University Medical Center Groningen

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

DNA methylation (epigenetics) using the Illumina MethylationEPIC kit. Changes in DNA methylation at gene promoter/enhancer sites will be correlated through the NetworkAnalyst platform.

Time Frame: baseline versus 3 months follow up

The primary objective of the current project is to measure changes in DNA methylation (i.e. epigenetics) of blood leukocytes between sepsis survivors at ED admission and three months after hospital discharge.

Gene expression (transcriptomics/qPCR) will be measured using the Illumina Hi-Seq instrument. Differential gene expression will be correlated through the NetworkAnalyst platform.

Time Frame: baseline versus 3 months follow up

The primary objective of the current project is to measure changes in gene expression (i.e. transcriptomics) of blood leukocytes between sepsis survivors at ED admission and three months after hospital discharge.

Secondary Outcomes

  • Mortality. Mortality status will be obtained from the Municipal Personal Records Database (BRP), containing reliable and complete registration all Dutch citizens(1 year)
  • Intoxications(3 months)
  • Medication use(3 months)
  • Physical activity (e.g. Short Questionnaire to Assess Health-Enhancing Activity) (SQUASH) and 'Utrechtse activiteiten lijst' (UAL))(3 months)
  • Nutrition status measured with PS-SGA Short Form and SNAQ form. (both questionnaires)(3 months)
  • Sepsis severity defined with SOFA score(3 months follow up)
  • Somatic symptoms (e.g. Patient Health questionnaire-15)(3 months)
  • Activities of daily living as determined by EQ-5D-5L (if abnormal also Katz-ADL-6)(3 months)
  • Co-morbidity (a.o. Charlson comorbidity index)(3 months)
  • Length-of-stay in hospital/intensive care unit (ICU)(0-3 months)
  • Fatigue assessed with piper fatigue scale(3 months)
  • Mood assessed with the Patient Health Questionnaire-2 ( (questionnaire)(3 months)
  • Demographics(3 months)
  • Vital parameters(At baseline and three months.)

Study Sites (1)

Loading locations...

Similar Trials